Archives
-
PD0325901: Linking MEK Signals to Chromatin State
2026-08-26
Explore how PD0325901 can serve as a mechanistic perturbation tool for connecting MEK–ERK activity with cell-cycle control, apoptosis, and chromatin accessibility. This article pairs established pharmacology with the single-molecule nucleosome insights of IDLI to improve assay design and interpretation.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-08-25
Phalloidin B7678 provides high-affinity binding and stabilization of filamentous actin for endpoint cytoskeleton visualization in fixed or permeabilized samples. It is not appropriate for live-cell imaging or experiments that require reversible actin remodeling because it can alter the native F-actin and G-actin equilibrium.
-
MOG (35-55) Peptide for EAE Research
2026-08-25
MOG (35-55) is a myelin oligodendrocyte glycoprotein peptide used to induce experimental autoimmune encephalomyelitis in preclinical multiple sclerosis research. Its defined handling range supports antigen-driven neuroinflammation assays, while recent EAE work links disease modulation to PARP7, STAT1/STAT2, and type I interferon signaling.
-
Bleomycin Sulfate: From DNA Damage to Fibrosis
2026-08-24
Bleomycin Sulfate is more than a DNA strand-break inducer: it is a controllable bridge between cancer biology, immune injury, and pulmonary fibrosis research. This article explains how to use the model to connect genomic damage with macrophage-specific STING signaling and improve translational assay design.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-24
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition with reduced renal fibrosis, inflammation, and epithelial-to-mesenchymal transition. By combining AZ505 and LLY507 in an animal model with tubular epithelial-cell experiments, the work provides a useful framework for evaluating SMYD2 inhibitor activity in kidney injury and fibrosis research.
-
CD163+ Macrophages Drive Granulosa Cell Apoptosis in PCOS
2026-08-23
The reference study links elevated CD163 activity in ovarian macrophages with inflammatory signaling, soluble CD163 release, and granulosa cell apoptosis in polycystic ovary syndrome. Its integrated use of transcriptomics, patient samples, a DHEA-induced mouse model, and macrophage–granulosa cell co-culture provides a useful framework for studying immune regulation of follicular dysfunction.
-
Quizartinib (AC220): From Target to Translation
2026-08-22
Quizartinib (AC220) offers a precise way to connect FLT3 target engagement with leukemia-cell response. This article develops a translational assay framework linking AML models, resistance biology, and the emerging FLT3–TAZ axis in blast-phase CML.
-
Praeruptorin A Targets ERK/MMP1 in HCC Metastasis
2026-08-21
The reference study shows that praeruptorin A suppresses migration and invasion of human hepatocellular carcinoma cells without evident cytotoxicity or cell-cycle disruption. Its key mechanistic contribution is linking this antimetastatic phenotype to ERK activation and MMP1 downregulation, with ERK silencing reversing both molecular and functional effects.
-
Disulfiram Workflows for Proteasome and Pyroptosis Research
2026-08-20
Disulfiram provides a practical bridge between copper-sensitive proteasome assays, apoptotic cancer cell death induction, and emerging GSDMD-focused pyroptosis studies. This workflow-led guide covers solvent handling, dose design, orthogonal readouts, troubleshooting, and how to interpret results in breast cancer and inflammasome models.
-
From Neem Biology to Translational qPCR
2026-08-20
Neem leaf extract research connects oxidative-stress biology with a practical need for rigorous transcriptional validation. This thought-leadership guide explains how dye-based qPCR, specificity controls, and disciplined assay design can help translational teams evaluate findings involving catalase, reactive oxygen species, and cellular senescence without overstating preclinical evidence.
-
Dimetridazole: Mechanism and Research Uses
2026-08-19
Dimetridazole, also called 1,2-Dimethyl-5-nitroimidazole, is a nitroimidazole research compound with strain- and medium-dependent antimicrobial activity. A peer-reviewed Pseudomonas aeruginosa study supports its evaluation as a quorum sensing inhibitor and combination-enhancing agent, but the evidence does not establish clinical efficacy or universal antibacterial activity.
-
Proteinase K for High-Integrity DNA Workflows
2026-08-19
Proteinase K combines broad protein digestion with resilience to SDS, EDTA, and varied temperatures, making it a practical choice for genomic DNA isolation and enzyme contaminant removal. This guide translates its biochemical profile into executable workflows, assay controls, and troubleshooting decisions for reliable downstream molecular biology.
-
Dimetridazole Resensitizes MDR E. coli to Cefotaxime
2026-08-18
A 2025 Scientific Reports study found that Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole, potentiated cefotaxime against a multidrug-resistant Escherichia coli isolate. Checkerboard, microscopy, fatty-acid, gene-expression, and Galleria mellonella experiments linked the combination effect to impaired membrane integrity, permeability, and lipid biosynthesis, providing a proof-of-concept framework for antibiotic-rescue research.
-
Amikacin in CREC Resistance Assays
2026-08-18
Amikacin and BAY416651 can help researchers connect aminoglycoside exposure with resistance genotype, plasmid mobility, and bacterial protein synthesis. This guide translates recent CREC transmission findings into practical assay design and interpretation decisions.
-
Measuring Cancer Drug Responses Beyond Viability
2026-08-17
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of cancer drug response. Its central contribution is a framework that separates proliferative arrest from cell killing and emphasizes their different magnitudes and timing, improving interpretation of in vitro pharmacology.